Tyrosine Kinase Inhibitors: all 10,744 studies that test it
Page 86 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.
- Pazopanib for Metastatic Alveolar Soft Part SarcomaTerminatedNCT02113826Phase 2
- Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous LeukemiaCompletedNCT02113319Phase 2
- A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult SubjectsCompletedNCT02111317Phase 1
- Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
- A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic AlterationsTerminatedNCT02109016Phase 2
- Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine TumorsWithdrawnNCT02108782Phase 2
- Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.CompletedNCT02106845Phase 1
- A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523CompletedNCT02105129Phase 1
- Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed ConditionsCompletedNCT02103322Phase 2/3
- Drug Interaction Study Between Bosutinib And DabigatranCompletedNCT02102633Phase 1
- Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade GliomaCompletedNCT02101905Phase 1
- The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord InjuryCompletedNCT02099890Phase 3
- Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.CompletedNCT02097810Phase 1
- Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy VolunteersCompletedNCT02097433Phase 1
- A Phase 1/2 Study Evaluating AMG 337 in Asian SubjectsCompletedNCT02096666Phase 1/2
- Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)TerminatedNCT02095717Phase 2
- Regorafenib and Cetuximab in Patients With Advanced MalignancyCompletedNCT02095054Phase 1
- Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)TerminatedNCT02093429Phase 1/2
- Optimizing Pazopanib Exposure in RCC PatientsTerminatedNCT02089802Phase 2
- MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).CompletedNCT02088112Phase 1
- Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib TherapyTerminatedNCT02086487Phase 4
- SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone PainCompletedNCT02085603Phase 2
- Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical StudyCompletedNCT02084732Phase 2
- Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy SubjectsCompletedNCT02084199Phase 1
- A Phase I Dose Escalation Study of Erlotinib in Combination With TheophyllineTerminatedNCT02080078Phase 1
- Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AMLCompletedNCT02076191Phase 1/2
- CRIZENT: Crizotinib and Sunitinib in Metastatic Breast CancerTerminatedNCT02074878Phase 1
- T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast CancerCompletedNCT02073916Phase 1
- Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by SurgeryCompletedNCT02072486Not applicable
- Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.TerminatedNCT02072057Phase 2
- Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs TherapyStatus unknownNCT02072044Phase 2
- Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）Status unknownNCT02072031Phase 2
- PLX3397 KIT in Acral aNd mucOsal MelanomaCompletedNCT02071940Phase 2
- Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell CarcinomaTerminatedNCT02071641Phase 2
- A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of GenesCompletedNCT02069730Not applicable
- Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular CancerCompletedNCT02069145Phase 1
- Pharmacokinetic Comparison of XS003 and TasignaCompletedNCT02068898Phase 1
- Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal MelanomaActive, not recruitingNCT02068586Phase 2
- Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKIStatus unknownNCT02066870Phase 1
- Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid ChondrosarcomaCompletedNCT02066285Phase 2
- Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationStatus unknownNCT02066038Phase 2
- A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADTWithdrawnNCT02065323Phase 2
- Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLCCompletedNCT02064491Phase 2
- Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic InsufficiencyStatus unknownNCT02062515Phase 2
- Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.CompletedNCT02058901Phase 1
- A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib TrialCompletedNCT02057380Phase 2
- A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast CancerCompletedNCT02053636Phase 2
- Study of the Combination of Tivantinib Plus Pemetrexed and CarboplatinCompletedNCT02049060Phase 1/2
- Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic CancerWithdrawnNCT02048943Phase 1
- Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's DiseaseCompletedNCT02048618Phase 2
- A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and LymphomasCompletedNCT02048488Phase 1/2
- Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)WithdrawnNCT02044601Phase 1/2
- Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR MutationCompletedNCT02044328Phase 2
- A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line SettingStatus unknownNCT02041260Phase 2
- Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC PatientsCompletedNCT02040064Phase 1
- Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLCCompletedNCT02039336Phase 1/2
- An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid TumorsCompletedNCT02038673Phase 1
- Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLCStatus unknownNCT02037997Phase 2
- Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung caStatus unknownNCT02036359Phase 2
- Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02035527Phase 1
- Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1CompletedNCT02034981Phase 2
- Icotinib Hydrochloride in Treating Patients With Advanced CancersWithdrawnNCT02033148Phase 1
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular LymphomaTerminatedNCT02031419Phase 1
- To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung CancerStatus unknownNCT02029209Phase 2/3
- A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)CompletedNCT02029157Phase 3
- High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable DiseaseStatus unknownNCT02027090Phase 2
- Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic CancerStatus unknownNCT02024633Phase 1
- The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori InfectionStatus unknownNCT02018328Not applicable
- A Food Effect Phase I Study of the Volitinib in Healthy SubjectsCompletedNCT02017236Phase 1
- Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid TumorsTerminatedNCT02016534Phase 2
- Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain TumorsStatus unknownNCT02015728Not applicable
- Ruxolitinib in the Treatment of Chronic Lymphocytic LeukemiaCompletedNCT02015208Phase 1/2
- Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver MetastasisCompletedNCT02015169Phase 2
- Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)CompletedNCT02014636Phase 1
- Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)CompletedNCT02013648Phase 3
- A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02013219Phase 1
- Ublituximab + Ibrutinib in Select B-cell MalignanciesCompletedNCT02013128Phase 1/2
- A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC StudyStatus unknownNCT02013089Not applicable
- Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung CancerStatus unknownNCT02009605Phase 2
- ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix CancerCompletedNCT02009579Phase 2
- Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of RecurrenceTerminatedNCT02009423Phase 3
- Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell MalignanciesCompletedNCT02006485Phase 1
- A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule FormulationCompletedNCT02006277Phase 1
- Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)Status unknownNCT02006043Phase 2
- Phase I Clinical Study of Metatinib Tromethamine TabletCompletedNCT02004548Phase 1
- Effect of Neomycin on the Pharmacokinetics of RegorafenibCompletedNCT02001909Phase 1
- Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR MutationStatus unknownNCT02001896Phase 3
- Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid LeukaemiaCompletedNCT02001818Phase 2
- A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma MalignanciesCompletedNCT02000934Phase 1
- Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.TerminatedNCT02000453Phase 1
- Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT01998828Phase 2
- Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerCompletedNCT01998126Phase 1
- Continuation of TKI With or Without Chemotherapy Beyond Gradual ProgressionStatus unknownNCT01998061Phase 2
- Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal CancerCompletedNCT01996969Not applicable
- Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR MutationTerminatedNCT01996098Phase 3
- A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorTerminatedNCT01994213Phase 2
- MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)Active, not recruitingNCT01991379Phase 1/2
- A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.CompletedNCT01991184Phase 1
- Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerActive, not recruitingNCT01990196Phase 2
- Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid TumorsCompletedNCT01985555Phase 1